Gesine Respondek1,2, Johannes Levin2,3, Günter U Höglinger1,2. 1. Department of Neurology, Technische Universität München. 2. German Center for Neurodegenerative Diseases (DZNE). 3. Klinik für Neurologie, Klinikum der Ludwig Maximilians Universität München, Munich, Germany.
Abstract
PURPOSE OF REVIEW: This update discusses novel aspects on clinicopathological concepts and therapeutic challenges in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), arising from publications of the last 1.5 years. RECENT FINDINGS: The clinical criteria for diagnosis of PSP have been revised. Clinical variability of pathologically defined PSP and MSA makes the development of mature biomarkers for early diagnosis and biomarker-based trial design indispensable. Novel molecular techniques for biomarker supported diagnosis of PSP and MSA and for monitoring disease progression are being studied. Research in the pathophysiology of both diseases generates gradual progress in the understanding of the underlying processes. Several promising disease-modifying therapeutic approaches for PSP and MSA are now moving into clinical trials. SUMMARY: Recent research generates insights in the pathophysiological relevant processes and raises hope for earlier clinical diagnosis and disease-modifying therapies of patients with PSP and MSA.
PURPOSE OF REVIEW: This update discusses novel aspects on clinicopathological concepts and therapeutic challenges in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA), arising from publications of the last 1.5 years. RECENT FINDINGS: The clinical criteria for diagnosis of PSP have been revised. Clinical variability of pathologically defined PSP and MSA makes the development of mature biomarkers for early diagnosis and biomarker-based trial design indispensable. Novel molecular techniques for biomarker supported diagnosis of PSP and MSA and for monitoring disease progression are being studied. Research in the pathophysiology of both diseases generates gradual progress in the understanding of the underlying processes. Several promising disease-modifying therapeutic approaches for PSP and MSA are now moving into clinical trials. SUMMARY: Recent research generates insights in the pathophysiological relevant processes and raises hope for earlier clinical diagnosis and disease-modifying therapies of patients with PSP and MSA.
Authors: Wolfgang H Jost; Paul Lingor; Lars Tönges; Johannes Schwarz; Carsten Buhmann; Jan Kassubek; Anette Schrag Journal: J Neural Transm (Vienna) Date: 2019-05-13 Impact factor: 3.575
Authors: Olivia J Conway; Minerva M Carrasquillo; Xue Wang; Jenny M Bredenberg; Joseph S Reddy; Samantha L Strickland; Curtis S Younkin; Jeremy D Burgess; Mariet Allen; Sarah J Lincoln; Thuy Nguyen; Kimberly G Malphrus; Alexandra I Soto; Ronald L Walton; Bradley F Boeve; Ronald C Petersen; John A Lucas; Tanis J Ferman; William P Cheshire; Jay A van Gerpen; Ryan J Uitti; Zbigniew K Wszolek; Owen A Ross; Dennis W Dickson; Neill R Graff-Radford; Nilüfer Ertekin-Taner Journal: Mol Neurodegener Date: 2018-10-11 Impact factor: 14.195
Authors: F Nemmi; A Pavy-Le Traon; O R Phillips; M Galitzky; W G Meissner; O Rascol; P Péran Journal: Neuroimage Clin Date: 2019-05-13 Impact factor: 4.881